H1N1 Neuraminidase Antibody | 5245

H1N1 Neuraminidase Antibody | 5245 | Gentaur UK, US & Europe Distribution

Host: Rabbit

Reactivity: Virus

Homology: N/A

Immunogen: Neuraminidase antibody was raised against synthetic peptides from the seasonal influenza (H1N1) Neuraminidase protein and the novel swine influenza Neuraminidase protein.
The antibody recognizes both variants.
The immunogen is located within the first 50 amino acids of H1N1 Neuraminidase.

Research Area: Infectious Disease

Tested Application: E

Application: Neuraminidase antibody can be used for the detection of the Neuraminidase protein from the seasonal influenza A (H1N1) and the novel swine influenza in ELISA. It will detect 2 ng of free peptide at 1 μg/mL.

Specificiy: This antibody will recognize the Neuraminidase from the both the seasonal influenza (H1N1) and swine-origin influenza virus (A/California/14/2009 (H1N1) ) .

Positive Control 1: N/A

Positive Control 2: N/A

Positive Control 3: N/A

Positive Control 4: N/A

Positive Control 5: N/A

Positive Control 6: N/A

Molecular Weight: N/A

Validation: N/A

Isoform: N/A

Purification: H1N1 Neuraminidase Antibody is affinity chromatography purified via peptide column.

Clonality: Polyclonal

Clone: N/A

Isotype: IgG

Conjugate: Unconjugated

Physical State: Liquid

Buffer: H1N1 Neuraminidase Antibody is supplied in PBS containing 0.02% sodium azide.

Concentration: 1 mg/mL

Storage Condition: H1N1 Neuraminidase antibody can be stored at 4˚C for three months and -20˚C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.

Alternate Name: H1N1 Neuraminidase Antibody:

User Note: Optimal dilutions for each application to be determined by the researcher.

BACKGROUND: H1N1 Neuraminidase Antibody: Influenza A virus is a major public health threat, killing more than 30, 000 people per year in the USA. In early 2009, a novel swine-origin influenza A (H1N1) virus was identified in specimens obtained from patients in Mexico and the United States. The virus spread quickly around the world and on June 11, 2009, the World Health Organization declared it a pandemic. Influenza A virus has one of sixteen possible Hemagglutinin (HA) surface proteins and one of nine possible Neuraminidase (NA) surface proteins. The Hemagglutinin protein facilitates viral attachment while Neuraminidase is involved in viral release. These proteins also elicit immune responses that prevent infection or independently reduce viral replication. The genetic make-up of this swine flu virus is unlike any other: it is an H1N1 strain that combines a triple assortment first identified in 1998 including human, swine, and avian influenza with two new pig H3N2 virus genes from Eurasia, themselves of recent human origin. The distinct antigenic properties of the new swine influenza virus compared with seasonal influenza A (H1N1) virus suggest that human immunity against new swine influenza virus is limited, although the age distribution of reported cases suggests some degree of protection in older age groups.